Bacteria are central to human health and disease, but the tools available for modulating and 16 editing bacterial communities are limited. New technologies for tuning microbial populations 17 would facilitate the targeted manipulation of the human microbiome and treatment of bacterial 18 infections. For example, antibiotics are often broad spectrum in nature and cannot be used to 19 accurately manipulate bacterial communities. Bacteriophages can provide highly specific 20 targeting of bacteria, but relying solely on natural phage isolation strategies to assemble well-21 defined and uniform phage cocktails that are amenable to engineering can be a time-consuming 22 and labor-intensive process. Here, we present a synthetic-biology strategy to modulate phage 23 host ranges by manipulating phage genomes in Saccharomyces cerevisiae. We used this 24 technology to swap multiple modular phage tail components and demonstrated that Escherichia 25 coli phage scaffolds can be redirected to target pathogenic Yersinia and Klebsiella bacteria, and 26 conversely, Klebsiella phage scaffolds can be redirected to target E. coli. The synthetic phages 27 achieved multiple orders-of-magnitude killing of their new target bacteria and were used to 28 selectively remove specific bacteria from multi-species bacterial communities. We envision that 29 this approach will accelerate the study of phage biology, facilitate the tuning of phage host 30 ranges, and enable new tools for microbiome engineering and the treatment of infectious diseases. 31 32 65 their manipulation within bacterial hosts. Finally, all existing approaches are limited in the 66 number of mutations that can be introduced simultaneously. Multiple rounds of mutations are 67 therefore often required, making the process inefficient. Here, we demonstrate a high-throughput 68 phage-engineering platform that leverages the tools of synthetic biology to overcome these 69 challenges and use this platform to engineer model phages with tunable host ranges. 70 71
INTRODUCTION
Bacteriophages (phages) are natural biological nanomachines that have evolved to infect host 34 bacteria with exquisite specificity and efficacy. Phages constitute the most abundant type of 35 biological particles on earth (Hendrix, 2003) and reproduce at the expense of their host bacteria. 36 Thus, phages have been explored as a means of controlling pathogenic bacteria (d'Herelle, 1931) , 37 but poor understanding of the molecular relationships between bacteria and their phages can lead 38 to highly variable treatment outcomes (Brussow, 2012) . With the rise of drug-resistant bacterial 39 infections and the sharp decline in antibiotic discovery and development (Fischbach and Walsh, 40 2009), phage therapy is regaining attention after years of declining interest in the Western world 41 (Carlton, 1999) . Furthermore, despite the important role that the microbiome plays in regulating 42 human health and disease (Grice and Segre, 2012) , strategies for precisely manipulating complex 43 microbial communities are lacking. With their ability to kill or deliver DNA into specific 44 bacteria, phages constitute a promising technology for manipulating microbiota. However, the 45 limited host range of most naturally isolated phages is a major barrier to the development and 46 approval of commercially available phage-based products. Conventional strategies for 47 identifying phages with specific host ranges rely on screening samples from nature. Naturally 48 isolated phages are often very diverse in morphology, genomic content, and life cycles, which 49 poses a challenge for the engineering, manufacturing, and regulatory approval of phages as 50 biotechnologies. For example, phage cocktails have been used to address the limited host range 51 of any single phage (Sulakvelidze et al., 2001) . However, the desire to increase coverage by 52 adding more members to a phage cocktail is counterbalanced with the challenge of producing 53 and testing well-defined multi-component mixtures for regulatory approval. 54 Creating phage-based therapeutics and diagnostics is also limited by the difficulty of 55 engineering phages. Lytic phage DNA does not reside for very long inside of bacteria; this 56 makes it difficult to modify phage genomes during the phage reproductive cycle. Phage genomes 57 are also often too large to be handled in vitro. Phage genome engineering is thus classically 58 carried out with allele replacement methods, whereby a piece of the phage genome is cloned into 59 an appropriate bacterial vector and remodeled using classical molecular biology, and the 60 bacterium containing the resulting construct is then infected with the phage, allowing the phage 61 to recombine with the plasmid to acquire the desired mutations. This process is inefficient 62 because many phages degrade resident DNA upon entry, and time-consuming due to the absence 63 of phage selectable markers to expedite screening of output viral populations. Furthermore, there 64 are very large stretches of phage DNA that encode products toxic to bacteria, thus preventing yeast clones in order to verify proper DNA assembly, to eliminate the possibility of unwanted 92 mutations, and to help determine potential reasons for the failure of the synthetic phage genome 93 to produce viable offspring. 94 We targeted phages from the T7-family because their life cycle is largely host 95 independent (Qimron et al., 2010) and there is a relatively large number of family members for 96 which genomic sequences are publicly available. These include T7 (coliphage, 39,937 bp), T3 97 (coliphage, 38,208 bp) , K1E (K1-capsule-specific coliphage, 45,251 bp), K1F (K1-capsule-98 specific coliphage, 39,704 bp), K1-5 (K1-or K5-capsule-specific coliphage, 44,385 bp), SP6 99 (Salmonella phage, 43,769 bp), LUZ19 (Pseudomonas phage, 43,548 bp), gh-1 (Pseudomonas 100 phage, 37,359 bp), K11 (Klebsiella phage, 41,181 bp), and others. We first sought to confirm 101 that purified phage DNA from various phages could be transformed into bacterial hosts to 102 generate functional phages. We used E. cloni 10G® (10G) cells (Durfee et al., 2008 ) as a one-103 time phage propagation host. Except for T7 and T3, all phages used in this study (K1E, K1F, K1-104 5, SP6, LUZ19, gh-1, and K11) cannot infect 10G ( Figure 1B) . We extracted the genomes of a 105 diversity of phages from purified phage particles. Each genome was electroporated into 10G 106 directly. After incubation and chloroform treatment, supernatants were mixed with overnight 107 cultures of each natural host bacteria for each phage in soft agar, poured onto agar plates, and 108 incubated, looking for plaque formation ( Figure 1C and 1D) . We found that all the phages tested Rebooting bacteriophages from PCR products via the yeast platform. 115 To determine whether phage genomes assembled in yeast remain viable, we first attempted to 116 capture and then reboot T7 ( Figure 1E ), T3, and LUZ19 phages. We used PCR to amplify the 117 YAC pRS415 and add arms homologous to the ends of the phage genomes. We co-transformed 118 the YAC amplicons with phage genomic DNA into yeast. Confirmed YAC-phage constructs 119 were extracted from yeast and transformed into E. cloni 10G. These cells were then chloroform 120 treated and the resulting lysates were assessed for plaque-forming units (pfu) on the natural 121 bacterial hosts of the phages (see Figure 1E for capturing and rebooting T7). All 3 phage 122 genomes yielded yeast clones that could be rebooted to viable phages using this strategy. 123 Next, we captured and rebooted eight different phages that target E. coli, Salmonella, 124 Pseudomonas, and Klebsiella (T7, T3, K1E, K1F, K1-5, SP6, gh-1, and K11) by assembling 125 overlapping 3.8-12 kbp-long PCR products spanning the phage genomes with the linearized 126 YAC in yeast (Figure 2A upper panel illustrates this process with T7 as an example). All eight 127 phages were rebooted from PCR fragments via yeast platform and formed plaques on their 128 natural host bacteria (data not shown). Thus, this approach enables the efficient assembly and 129 instantiation of functional recombinant phages, and allows us to potentially create any desired 130 phage genotype in one step from PCR products.
(gp17), the tail fiber (Dunn and Studier, 1983; Pajunen et al., 2002) . Alterations in the gp17 138 sequence have been linked to the recognition of different host receptors and shifting host ranges 139 (Molineux, 2006) . Thus, we hypothesized that exchanging gene 17 or fragments of gene 17 140 between T7, T3, and their relatives could be used to tune their host specificities ( Figure 2B ). This 141 is supported by previous data on naturally occurring hybrids between T7 and T3 whose host 142 range was mostly dictated by which gene 17 they harbored (Lin et al., 2012) . 143 We first examined the host range of T7 and T3 phage on a range of hosts to determine 144 bacterial panels that were differentially targeted by the two phages. T3 is described as incapable 145 of targeting many common laboratory E. coli K-12 strains (Molineux, 2006) , so we performed 146 plaque formation assays with four K-12 strains and a B strain (BL21) as a control. As shown in 147 Figure 2C , T7 plaqued efficiently on all strains, while T3 did not produce plaques on BW25113 148 and MG1655 at a detectable frequency (Efficiency Of Plating (EOP) below 10 -9 ). T3 exhibited 149 ~4 orders-of-magnitude reductions in adsorption efficiency on BW25113 and MG1655 150 compared with the permissive BL21 strain ( Figure 2D ). These results indicate that we can 151 differentiate between T7 and T3 using BW25113 or MG1655, which are only susceptible to T7. 152 The gp17 tail fibers of T7 and T3 can be split in two domains. The N-terminal 149 153 residues are thought to be necessary for the tail fiber to bind to the rest of the capsid while the 154 remaining C-terminal region forms a kinked shaft and harbors the recognition domain for host 155 receptors at its tip (Steven et al., 1988) . The N-terminal regions of T7 and T3 share 99% identity 156 at the protein level, while the C-termini exhibit 83% identity, with the last 104 amino acids of the 157 T3 protein showing only 62% of identity to the corresponding 99 amino acids of the T7 protein. 158 Therefore, we hypothesized that swapping the C-terminal domain between the two viruses would 159 result in exchanging the host ranges. We constructed synthetic phages, based on either the T7 or 160 T3 viral chassis, which carried engineered gene 17 alleles composed of fragments from the other 161 phage. Specifically, we created six synthetic phages: T7 phage with the wild-type T7 tail fiber 162 (T7 WT ), T7 phage with 410 amino acids of the C-terminal region of the T3 tail fiber (T7 T3(C-gp17) ), 163 T7 phage with the entire T3 tail fiber (T7 T3(gp17) ), T3 phage with the wild-type T3 tail fiber 164 (T3 WT ), T3 phage with 405 amino acids of the C-terminal region of the T7 tail fiber (T3 T7(C-gp17) ), 165 and T3 phage with the entire T7 tail fiber (T3 T7(gp17) ). T7 WT and T7 phages are the same at the 166 genetic level; however, T7 WT phage was created by capturing the T7 genome in yeast and then 167 rebooting this phage genome in bacteria and served as a control for the faithfulness of the 168 reconstruction process, whereas T7 was obtained from ATCC. The same applies to T3 WT and T3. 169 Each phage was assembled in yeast via six PCR fragments and was rebooted via transformation 170 into E. coli 10G (example schematics in Figure 2A ). No unexpected mutations were found in the 171 heterologous gp17 regions of the rebooted phages. 172 To examine the host specificities of our six engineered phages, we performed plaque 173 formation assays on a range of E. coli, Klebsiella, and Yersinia pseudotuberculosis (Y. ptb) 174 strains ( Figure 3 ). T3 T7(C-gp17) and T3 T7(gp17) plaqued on E. coli BW25113 and E. coli MG1655 at 175 a similar EOP as T7 and T7 WT , while T3, T3 WT, T7 T3(C-gp17) , and T7 T3(gp17) had >10 5 -fold-reduced 176 EOPs on these strains. In addition, T3, T7 T3(C-gp17) , and T7 T3(gp17) plaqued on E. coli ECOR16 177 while T7, T3 T7(C-gp17) , and T3 T7(gp17) did not. In addition, we also synthesized a codon-optimized 178 version of the tail fiber of the T7-like enterobacteriophage 13a and created synthetic T7 phages 179 containing the entire 13a tail fiber (T7 13a(gp17) ) or the C-terminal region of the 13a tail fiber 180 (T7 13a(C-gp17) ) ( Figure 2E , Table S2 ). Although T7 and T7 WT did not plaque on E. coli ECOR16, 181 both T7 13a(gp17) and T7 13a(C-gp17) were able to do so efficiently ( Figure 3) . These results 182 demonstrate that the C-terminal region of gp17 is a major host range determinant and that new 183 host ranges can be conferred onto T7-like phage scaffolds by engineering tail fibers. Interestingly, 184 T7 13a(C-gp17) efficiently infected E. coli BW25113 and MG1655, similar to T7 and T7 WT , but 185 T7 13a(gp17) did not, which suggests that the N-terminus of the phage 13a tail fiber can also alter 186 infectivity of the virus although the mechanism is still to be investigated. A second example of 187 this phenomenon can be found between T7 T3(C-gp17) (lane 3, Figure 3 ) and T7 T3(gp17) (lane 4, 188 Figure 3 ). While the former phage infected Y. ptb YPIII (albeit with a low EOP), the latter phage 189 as well as wild-type T3 did not. 190 191 Coliphage T3 with a Yersinia phage tail fiber infects both E. coli and Y. pseudotuberculosis. 192 We further demonstrated that gene swapping between phages could overcome species barriers by 193 designing synthetic phage based on T7 or T3 scaffolds that can infect bacteria other than E. coli. 194 We started with coliphage T3 and Yersinia phage R (38,284 bp), since their gp17's share 99.5% 195 identity at the protein level and differ by only 3 nucleotides in gene 17. We hypothesized that 196 these differences could be responsible for their divergent host ranges. Indeed, we were unable to 197 detect productive T3 infection of Y. ptb strains IP2666 and YPIII, which are known hosts for 198 phage R (Rashid et al., 2012) . Because we did not have access to phage R, we introduced the 199 desired mutations in T3 gene 17 by PCR so that it would encode the same tail fiber as phage R 200 ( Figure 4A ). The mutated gene 17 was then swapped into the genome of T3. Synthetic T3 phage 201 with the R tail fiber (T3 R(gp17) ) was able to infect Y. ptb IP2666 and YPIII. Interestingly, T3 R(gp17) 202 maintained the capacity to infect E. coli BL21 ( Figure 4B ), demonstrating that the introduced 203 mutations conferred a host range expansion and not just a host range shift. In addition to 204 plaquing assays, we further characterized the ability of T3 WT versus T3 R(gp17) to kill Y. ptb 205 IP2666 over time. After 1.5 h of treatment, T3 R(gp17) killed 99.999% of IP2666 while T3 had no 206 effect on the bacteria ( Figure 4C ). 207 208 Redirection of host range between coliphage and Klebsiella phage by swapping whole tail 209 components. 210 We further explored our ability to overcome species barriers by engineering phages with lower 211 similarity with one another. K11 is a Klebsiella phage that belongs to the T7-like family (Dietz et 212 al., 1990) . K11 has a similarly sized genome to T7 and shares gene synteny with T7. The average 213 homology between K11 and T7 is 59% among the genes that have homologs between the two 214 viruses. For comparison, T7 and T3 share 72% identity at the genomic level between 215 homologous genes. While T7 is a coliphage and does not infect Klebsiella, K11 infects 216 Klebsiella, such as Klebsiella sp. 390, but not E. coli (Figure 3 ) (Bessler et al., 1973) . Their 217 respective host range determinants, gp17, are very different and do not share any homology 218 outside of the N-terminal 150 amino acids, which is only 47% identical between the two proteins. 219 Specifically, the T7 gp17 encodes tail fibers while K11 gp17, which is 322 amino acids longer 220 than the T7 gp17, directs the synthesis of a tail spike, an enzymatic host range determinant that 221 actively breaks down the capsule of Klebsiella to allow K11 phage to gain access to unknown 222 secondary receptors located beneath the capsule (Bessler et al., 1973) . 223 To create a T7 phage with a K11 tail fiber and a K11 phage with a T7 tail fiber, we first 224 swapped the entire gene 17, but this yielded no viable phages. We then tried to construct 225 composite tail fibers composed of gene 17 fragments from both phages hybridized at various 226 points along the length of the gene, but this was also unsuccessful at generating functional 227 synthetic phages. We speculated that one possible reason for these failures could be that the K11 228 genome cannot create productive phages within E. coli 10G. However, the natural K11 genome 229 produced functional virions when it was electroporated into 10G cells, which were subsequently 230 lysed via chloroform and plated onto a suitable host ( Figure 1D and Table S1 ). 231 Alternatively, the gene 17 product from K11 may require a function or factor that is 232 absent from T7. Cuervo et al. reported that the tail of T7 phage, which assembles independently 233 of the head, is assembled from a dodecamer of gp11 (the adaptor) and an hexamer of gp12 (the 234 nozzle) ( Figure 5A ) onto which 6 trimers of gp17 attach (Cuervo et al., 2013) . T7's six tail fibers 235 attach at the interface between the adaptor and nozzle, thus making contacts with both proteins. 236 The adaptor ring is responsible for the attachment of the preformed tail to the prohead via 237 interactions with the portal composed of 12 subunits of gp8. The homology between the gp8 of 238 T7 and K11 (80% identity at the amino acid level) is much higher than the homology between 239 the gp11 and gp12 proteins of T7 and K11 (60 and 61% identity, respectively), which led us to 240 suspect that replacing all three tail genes of T7 with their K11 equivalents (gp11, gp12, and 241 gp17) could be necessary to create functional virions ( Figure 5B ). Indeed, both T7 with K11 tail 242 components (T7 K11(gp11-12-17) ) and K11 with T7 tail components (K11 T7(gp11-12-17) ) were 243 successfully engineered into functional phages that exhibited tail-dependent host ranges. 244 Specifically, T7 K11(gp11-12-17) infected Klebsiella sp. 390 and did not target E. coli, while 245 K11 T7(gp11-12-17) infected E. coli, but did not plaque on Klebsiella ( Figure 5C and Figure 3 ). The 246 yeast-based phage engineering platform enabled the facile construction of these phages via one-247 step genome construction even though gene 11 and 12 are physically separated from gene 17, a 248 feat that no other phage engineering method can currently achieve. To further validate the ability 249 of synthetic T7 K11(gp11-12-17) to target Klebsiella, we performed a time-course experiment that 250 showed that T7 K11(gp11-12-17) killed 99.955% of Klebsiella sp. 390 after 1 hour of treatment ( Figure   251 5D), but was about 100-fold less effective than K11 WT ( Figure 5C and Figure S1 ). Table S3 ). Furthermore, a phage cocktail consisting of two phages with the same chassis 270 but different host ranges, T7 WT and T7 K11(gp11-12-17) , resulted in >99% killing of Klebsiella sp. 390 271 and >99.9% killing of Y. ptb IP2666 after 1 hour, thus enriching for probiotic E. coli Nissle 1917 272 ( Figure 6 and Table S3 ). These results demonstrate the high efficiency and selectivity of our 273 engineered phages in microbial consortia, and the potential for combining well-defined phage 274 cocktails with probiotics. 275 277 In this study, we utilized an efficient yet simple yeast-based platform for phage engineering to 278 modulate phage host ranges for several members of the T7 phage family. Traditional phage 279 engineering strategies, such as in vitro manipulation, allele-exchange within bacterial hosts, and 280 phage crossing via co-infection of bacteria (Beier et al., 1977; Garcia et al., 2003; Lin et al., 281 2011) have been used to modulate phage host range (Tetart et al., 1998; Trojet et al., 2011; 282 Yoichi et al., 2005) , but these strategies are inefficient and unable to achieve multiple genetic 283 modifications in a single step. Screening for a desired mutation after classical crossing or 284 recombination experiments can require PCR, restriction digestion, or plaque hybridization on 285 hundreds of individual plaques, which are all costly and time-consuming methods. Conversely, 286 our strategy rarely requires the screening of more than a few yeast clones. Specifically, we found 287 that at >25% of our yeast clones contained properly assembled phage genomes (composed of up 288 to 11 DNA fragments) that could be used to generate functional plaques after transformation into 289 bacteria. Previously, a scheme for engineering phage T4 through electroporation of PCR 290 products was devised (Pouillot et al., 2010), but it is based on a particular feature of the genetic 291 regulation of T4 and cannot easily be applied to other phage families. Recently, the 5.4 kb 292 filamentous coliphage φX174 was assembled in yeast in order to stably store the genome and aid 293 in phage refactoring (Jaschke et al., 2012) . In this approach, the majority of the genome 294 assembly was performed in vitro and the YAC cloning was mostly used to store the resulting 295 genome, whereas the majority of the genome engineering in our approach stems from the actual 296 gap-repair cloning process in yeast. In addition, the phages we have cloned using this method are 297 in the 38-45 kbp range and we have indications that it can also be used for much larger phage 298 genomes (e.g., up to 100 kbp, data not shown). 299 More recently, type I-E CRISPR-Cas counter-selection has been shown to be a useful 300 tool to edit the genome of phage T7 (Kiro et al., 2014) . The S. pyogenes CRISPR-Cas9 system 301 was also shown to be functional on the heavily modified genomes of a few members of the T-302 even family, suggesting that it could be used to modify their genomes, although the authors did 303 not report any such attempts (Yaung et al., 2014) . We have successfully used the Streptococcus 304 pyogenes CRISPR-Cas9 system to select for mutants in phage T7 but with variable efficiencies 305 (data not shown). Thus, CRISPR-Cas systems can help to overcome some challenges associated 306 with engineering phage genomes in bacterial hosts for therapeutic applications (Bikard et al., 307 2014; Citorik et al., 2014; Goldberg et al., 2014; Kiro et al., 2014) . In contrast, leveraging yeast 308 to modify phages enables the decoupling of phage genome engineering from phage fitness and 309 viability, obviates the need for selective or screenable markers in phage genomes, reduces the 310 risks of phage contamination during the engineering process, and permits facile one-step genetic 311 manipulations. For example, the ability to simultaneously engineer multiple loci in a phage 312 genome was crucial for constructing K11 T7(gp11-12-17) and T7 K11(gp11-12-17) . However, a challenge of 313 yeast-based phage engineering (which is shared by in vitro strategies) is the need to reboot 314 modified phage genomes into functional phages. Here, we used high-efficiency DNA 315 transformation to deliver phage DNA into bacterial hosts, but future work may be facilitated by 316 in vitro transcription-translation systems capable of supporting functional phage synthesis (Shin   317   et al., 2012) . 318 In summary, we demonstrated that synthetic phages based on common viral scaffolds can 319 be designed to target a range of different bacterial hosts. Furthermore, we showed that a cocktail 320 containing multiple engineered phages could effectively remove select bacterial targets in mixed 321 microbial populations. We anticipate that the systematic and high-throughput engineering of 322 viral genomes will enable new applications and enhanced understanding of bacterial viruses. For 323 example, the engineering of common viral scaffolds could help simplify the discovery and 324 manufacturing of novel bacteriophages and reduce the regulatory burden required for the use of 325 phage cocktails as human therapeutics. Furthermore, abundant phage sequences contained within 326 metagenomic databases could be synthesized and booted into functional phage particles for study 327 and use. Finally, the systematic deconstruction and manipulation of these viral nanomachines 328 will enable a greater understanding of phage biology and may provide insights that are useful for 329 bioinspired nanotechnologies. Table S4 . Saccharomyces cerevisiae BY4741 (MATa 338 his3Δ1 leu2Δ0 met15Δ0 ura3Δ0) was obtained from Thermo Scientific. Escherichia coli strains reflect the total number of cells. Note that the chart does not allow the display of fractions 685 smaller than ~1%. The detailed data and the SEM are shown in Table S3 . The detection limit 686 was 2.0 × 10 3 CFU/ml. Klebsiella%sp.%390 Y.#ptb#IP2666 E.#coli#Nissle%1917 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15
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339 BL21 [B, F -ompT hsdS B (r B -m B -) gal dcm], DH5α [Κ−12, F -λ -Φ80d lacZΔM15 Δ(lacZYA- 340 argF)U169 deoR recA1 endA1 hsdR17 (r K -m K + ) phoA supE44 thi-1 gyrA96 relA1], BW25113 341 [K-12, F -λ -Δ(araD-araB)567 ΔlacZ4787(::rrnB-3) rph-1 Δ(rhaD-rhaB)568 hsdR514], MG1655 342 (K-12, F -λ -ilvG -rfb-50 rph-1),
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